Our short, quick and targeted approach mixes qualitative and quantitative analysis. By applying market data, history, science and quantitative methods; we synthesize metrics of pricing the RegMed universe. RMI incorporates market dynamics, answering crucial questions and generating actionable investment recommendations.
Understanding and knowing the answer as the release is issued requires a historical knowledge of sector pricing to more than “questimate” share perception and rebounds.
November 22, 2023
Happy Thanksgiving ... giving thanks and be SAFE!
July 3, 2023
Happy 4th of July and week
June 12, 2023
RegMed Investors (RMi) Research Note: Intellia Therapeutics (NTLA +$2.30 or +5.32% TO $45.54) pops on news of its CRISPR-based gene-editing drug almost completely eliminated attacks in a rare swelling disease
February 8, 2023
Cellectis SA (CLLS) closes 9.9 M ADS offering at $2.50
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at email@example.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors